{"nctId":"NCT00772382","briefTitle":"Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia","startDateStruct":{"date":"2008-12"},"conditions":["Chronic Kidney Disease","Dialysis","Hyperphosphatemia"],"count":116,"armGroups":[{"label":"MCI-196","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-196"]}],"interventions":[{"name":"MCI-196","otherNames":["Colestilan(INN)","Colestimide(JAN)","CHOLEBINE®","BindRen®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, and is \\>=18 years old\n* Stable hemodialysis or peritoneal dialysis\n* Subjects have stable phosphate control\n* Subjects on stabilized phosphorus diet\n* Subjects undergoing regular dialysis treatment\n* Females and of child-bearing potential have a negative serum pregnancy test\n* Male subjects must agree to use appropriate contraception\n\nExclusion Criteria:\n\n* Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose him/her to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study\n* serum albumin level \\< 3.0g/L\n* PTH level \\> 1000pg/mL\n* Hemoglobin level \\< 8mg/dL\n* A History of significant gastrointestinal motility problems\n* Biliary obstruction or proven liver dysfunction\n* A positive test for HIV 1 and 2 antibodies\n* A history of substance or alcohol abuse within the last year\n* Seizure disorders\n* A history of drug or other allergy\n* using cholestyramine, colestipol or colesevelam\n* Schedule to receive a kidney transplant within the next 6 months\n* Participation in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Adverse Events (AE)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Serum Phosphorus From Baseline to Week 52","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"2.05"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":63,"n":116},"commonTop":["Nausea","Vomiting","Diarrhoea","Decreased appetite","Haemodialysis-induced symptom"]}}}